Attention Hyperactivity Disorder is the most common neuropsychiatric disorder among children and adolescents (affecting about 3 to 5% of this age range). The major symptoms of ADHD are attention problems, hyperactivity and impulsivity. The condition persists during adult age in about 15% of cases
The most common prescribed drugs to treat ADH are psychostimulant (Methylphenidate, Amphetamine) and non-stimulant noradrenaline reuptake inhibitors (Atomoxetine).
A major objective of drug discovery targeting ADHD is developing new drugs with less undesirable side effects and better efficacy.
Watch the following 30 min webinar presented by our expert Jean-Charles Bizot to understand more how these 3 models operate:
Are you currently working on compounds targeting Attention Deficit Hyperactivity Disorders?
Please contact us for any additional information and we will gladly come back to you. We can also set up a dedicated meeting between you and our experts to discuss our CRO services and your research needs.